215 related articles for article (PubMed ID: 16279285)
21. [Genomics and clinical research for breast cancer].
Bertucci F; Birnbaum D
Med Sci (Paris); 2012 Mar; 28 Spec No 1():14-8. PubMed ID: 22494651
[TBL] [Abstract][Full Text] [Related]
22. [Clinical evaluation of new drugs].
Lewis PJ
Rev Prat; 1982 Sep; 32(41-42):2649-50 passim. PubMed ID: 7146802
[No Abstract] [Full Text] [Related]
23. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials.
Meric-Bernstam F; Brusco L; Shaw K; Horombe C; Kopetz S; Davies MA; Routbort M; Piha-Paul SA; Janku F; Ueno N; Hong D; De Groot J; Ravi V; Li Y; Luthra R; Patel K; Broaddus R; Mendelsohn J; Mills GB
J Clin Oncol; 2015 Sep; 33(25):2753-62. PubMed ID: 26014291
[TBL] [Abstract][Full Text] [Related]
24. Genomic research advances pancreatic cancer's early detection and treatment.
Brower V
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 26142448
[No Abstract] [Full Text] [Related]
25. The Cancer Therapy Evaluation Program of the National Cancer Institute.
Muggia FM; Carter SK; Macdonald JS
Semin Oncol; 1981 Dec; 8(4):394-402. PubMed ID: 7323811
[No Abstract] [Full Text] [Related]
26. Using "rationally designed drugs" rationally.
Brugarolas J; Clark JW; Chabner B
Lancet; 2003 May; 361(9371):1758-9. PubMed ID: 12781531
[No Abstract] [Full Text] [Related]
27. Designing transformative clinical trials in the cancer genome era.
Sleijfer S; Bogaerts J; Siu LL
J Clin Oncol; 2013 May; 31(15):1834-41. PubMed ID: 23589555
[TBL] [Abstract][Full Text] [Related]
28. NCI-MATCH launch highlights new trial design in precision-medicine era.
McNeil C
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 26142446
[No Abstract] [Full Text] [Related]
29. From oncogene to network addiction: the new frontier of cancer genomics and therapeutics.
Tonon G
Future Oncol; 2008 Aug; 4(4):569-77. PubMed ID: 18684067
[TBL] [Abstract][Full Text] [Related]
30. When to test new drugs in chemosensitive tumors?
Stoter G
Ann Oncol; 1992 Feb; 3(2):102. PubMed ID: 1606079
[No Abstract] [Full Text] [Related]
31. Phase 0 trials: are they ethically challenged?
Hill TP
Clin Cancer Res; 2007 Feb; 13(3):783-4. PubMed ID: 17289866
[No Abstract] [Full Text] [Related]
32. Rules of evidence and clinical recommendations on the use of antithrombotic agents.
Sackett DL
Chest; 1989 Feb; 95(2 Suppl):2S-4S. PubMed ID: 2914516
[No Abstract] [Full Text] [Related]
33. FDA seeks swifter approval of drugs for some life-threatening or debilitating diseases.
Marwick C
JAMA; 1988 Nov; 260(20):2976. PubMed ID: 3184360
[No Abstract] [Full Text] [Related]
34. The post-genomic red journal: charting the path from hope (not hype) to cure.
Shapiro SD
Am J Respir Cell Mol Biol; 2003 Oct; 29(4):425-6. PubMed ID: 14500252
[No Abstract] [Full Text] [Related]
35. The impact of genomic and proteomic technologies on the development of new cancer drugs.
Workman P
Ann Oncol; 2002; 13 Suppl 4():115-24. PubMed ID: 12401677
[No Abstract] [Full Text] [Related]
36. Incorporating genomics into the cancer clinical trial process.
Paik S
Semin Oncol; 2001 Jun; 28(3):305-9. PubMed ID: 11402440
[TBL] [Abstract][Full Text] [Related]
37. Traditional design does not choose values around 33%.
Ivanova A
Control Clin Trials; 2002 Apr; 23(2):183. PubMed ID: 11943446
[No Abstract] [Full Text] [Related]
38. [Ethics of randomization].
Arpaillange P; Dion S
Biomed Pharmacother; 1984; 38(9-10):426-9. PubMed ID: 6529599
[No Abstract] [Full Text] [Related]
39. Special issue of statistical genetics and genomics in clinical trials: guest editor's note.
Wu R; Lin M
J Biopharm Stat; 2010 Mar; 20(2):191-2. PubMed ID: 20309753
[No Abstract] [Full Text] [Related]
40. Cancer research. As questions grow, Duke halts trials, launches investigation.
Couzin-Frankel J
Science; 2010 Aug; 329(5992):614-5. PubMed ID: 20688986
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
